Jefferies & Co.

Jefferies & Co. is out with a research report on CenterPoint Energy (NYSE: CNP) and it has a Hold rating and a $20.50 price target on shares. in a note to clients, Jefferies & Co. writes, "CenterPoint reached a tentative agreement with the Texas PUC Staff and certain intervenors in its...

Jefferies & Co. is out with a research report on Wolverine World Wide (NYSE: WWW) and it has a Hold rating and a $40 price target on shares. In a note to clients, Jefferies & Co. writes, "WWW continues to capitalize on a favorable product (foootwear, oxfords, boots) and brand (Merrell,...

Jefferies & Co. is out with a research report on Titan International (NYSE: TWI) and it has a Buy rating and $30 price target on shares. In a note to clients, Jefferies & Co. writes, "After the close TWI issued updated guidance of $1.4 bln in revenue and $175-200 mln in EBITDA. Previous...

Jefferies & Co. is out with a research report on Vera Bradley, Inc. (NYSE: VRA) and it has a Buy rating and a $50 price target on shares. In a note to clients, Jefferies & Co. writes, "We like Vera Bradley's unique lifestyle brand positioning, early stage growth profile and opportunity to...

Jefferies & Co. is out with a research report on Lululemon Athletica (NASDAQ: LULU) and it has a Hold rating and a $59 price target on shares. In a note to clients, Jefferies & Co. writes, "LULU is down 5% on management's comments around LT operating margins at a competitor conference....

Jefferies & Co. is out with a research report on Boeing (NYSE: BA) and it has a Buy rating and a $90 price target on shares. In a note to clients, Jefferies & Co. writes, "With the delivery of the first B787 to launch customer, ANA, Boeing is now in the position of demonstrating that it...

Jefferies & Co. is out with a research report on ImmunoGen Inc. (NASDAQ: IMGN) and it has a Buy rating and a $19 price target on shares. In a note to clients, Jefferies & Co. writes, "The PFS benefit from the T-DM1 Phase 2 data in first-line HER2+ metastatic breast cancer (MBC) will be...

Jefferies & Co. is out with a research report on Intuit (NASDAQ: INTU) and is raising its price target to $55 from $53 and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "INTU reaffirmed FY12 guidance, strategy and confidence in multi-year double-digit organic...

Jefferies & Co. is out with a research report on Boston Private Financial (NASDAQ: BPFH) and is lowering its price target to $6.50 from $7, and it has a Hold rating on shares. In a note to clients, Jefferies & Co. writes, "Post our meeting with CEO Clay Deutsch, we remain comfortable with...

Jefferies & Co. is out with a research report on Salesforce.com (NYSE: CRM) and is reiterating its Buy rating and $156 price target on shares. In a note to clients, Jefferies & Co. writes, "CRM announced the acquisition of Assistly, a cloud-based customer service platform, which enhances...

Jefferies & Co. is out with a research report on Adobe Systems (NASDAQ: ADBE). In the note, Jefferies & Co. writes, "Given recent declines in stocks, we screened our coverage universe on NTM EV/Sales and NTM P/E with respect to: i) peak multiples from CY2006 onward; ii) trough multiples...

Jefferies & Co. is out with a research report on Susser Holdings (NASDAQ: SUSS) and is raising its price target to $26 from $20, and it has a Buy rating on shares. In a note to clients, Jefferies & Co. writes, "While the near-term outlook looks quite robust, with rig counts and sales tax...

Jefferies & Co. is out with a research report on Oracle (NASDAQ: ORCL) and it has a Buy rating and a $35 price target following earnings. In a note to clients, Jefferies & Co. writes, "ORCL reported F1Q12 results in-line with expectations (excl. $0.01 benefit from tax) and guided a better...

Jefferies & Co. is out with a research report on Xilinx Corp (NASDAQ: XLNX) and is lowering its price target to $35 from $38, but is keeping its Hold rating on shares. In a note to clients, Jefferies & Co. writes, "We are incrementally more positive on XLNX after the company lowered Q3...

Jefferies & Co. is out with a research report on Optimer Pharm. (NASDAQ: OPTR) and it has a Buy rating and a $17 price target on shares. In a note to clients, Jefferies & Co. writes, "Given much better-than-expected DIFICID sales in its early launch cycle (U.S. launch on 7/18/11), upcoming...